Table 2.

Associations with mortality and multivariable model with co-trimoxazole

	12 month survival probability	Unadjusted hazard ratio (HR)*	p	Adjusted hazard ratio (HR)*	p
Co-trimoxazole
No	0.87	Referent	<0.001	Referent	<0.001
Yes	0.92	0.60 (0.53–0.68)		0.64 (0.57–0.72)
Age (years)
≤30	0.92	Referent	0.03	Referent	0.2
31–35	0.91	1.1 (0.90–1.3)		1.1 (0.88–1.3)
36–40	0.89	1.2 (0.99–1.4)		1.2 (0.97–1.4)
41–45	0.88	1.3 (1.1–1.5)		1.3 (1.0–1.5)
>45	0.88	1.3 (1.1–1.5)		1.2 (0.98–1.4)
Sex
Men	0.88	Referent	<0.001	Referent	0.1
Women	0.92	0.75 (0.66–0.86)		0.89 (0.77–1.0)
CD4, cART initiation (cells/mm3)
<200	0.87	Referent	<0.001	Referent	<0.001
200–350	0.95	0.32 (0.27–0.39)		0.38 (0.32–0.47)
>350	0.96	0.31 (0.23–0.44)		0.35 (0.25–0.49)
Log10 HIV RNA at cART initiation		2.1 (1.9–2.4)	<0.001
WHO stage at cART initiation
Stage 1 or 2	0.94	Referent	<0.001	Referent	<0.001
Stage 3	0.90	1.6 (1.4–1.9)		1.4 (1.2–1.6)
Stage 4	0.85	3.1 (2.7–3.5)		2.2 (1.9–2.6)
Prior tuberculosis
No	0.91	Referent	<0.001	Referent	0.03
Yes	0.86	1.6 (1.4–1.8)		1.2 (1.0–1.3)
Time updated CD4 (cells/mm3)
<50	0.56	Referent	<0.001
50–100	0.79	0.36 (0.31–0.42)
100–200	0.90	0.15 (0.13–0.17)
200–350	0.96	0.060 (0.051–0.072)
>350	0.97	0.040 (0.033–0.053)
Time updated virologic suppression
≥400	0.68	Referent	<0.001	Referent	<0.001
<400	0.95	0.11 (0.10–0.13)		0.12 (0.10–0.13)
Isoniazid preventive therapy
None	0.89	Referent	<0.001
Received	0.94	0.56 (0.44–0.70)

^*controlling for clinic level effects using frailty random effects